Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268]
Lung Cancer. 2021 Aug:158:166-167.
doi: 10.1016/j.lungcan.2021.05.035.
Epub 2021 Jun 11.
1 State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
3 The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China.
4 The First Hospital of Jilin University, Changchun, China.
5 Jiangsu Province Hospital, Nanjing, China.
6 Beijing Chest Hospital, Capital Medical University, Beijing, China.
7 Jilin Cancer Hospital, Changchun, China.
8 BeiGene (Beijing) Co., Ltd., Beijing, China.
9 State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zlhuxi@163.com.